cbp8
Small moleculeexperimentalImaging agent
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2018 (NCT03535545)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 68-gallium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06532071 | Phase 2 | Sep 1, 2024 | Harvard University |
| NCT05619302 | Phase 3 | Jan 3, 2023 | Harvard University |
| NCT05417776 | Phase 2 | Sep 1, 2022 | Boehringer Ingelheim, Harvard University |
| NCT04485286 | Phase 2 | Oct 31, 2020 | Harvard University, National Cancer Institute (NCI) |
| NCT03535545 | Phase 1 | Aug 1, 2018 | Harvard University, National Heart, Lung, and Blood Institute (NHLBI) |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 5 | 5 | 3 | 2018 |
| Boehringer Ingelheim | For profit | 1 | 0 | 1 | 2022 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2020 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2018 |
4 organizations
Page 1 / 1